General Information of Drug (ID: DMU8KOD)

Drug Name
Anakinra
Synonyms Kineret; Kineret (TN); Anakinra (USAN/INN)
Indication
Disease Entry ICD 11 Status REF
Rheumatoid arthritis FA20 Approved [1]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [2]
CINCA syndrome N.A. Investigative [3]
Therapeutic Class
Antiinflammatory Agents
Sequence
MRPSGRKSSKMQAFRIWDVNQKTFYLRNNQLVAGYLQGPNVNLEEKIDVVPIEPHALFLG
IHGGKMCLSCVKSGDETRLQLEAVNITDLSENRKQDKRFAFIRSDSGPTTSFESAACPGW
FLCTAMEADQPVSLTNMPDEGVMVTKFYFQEDE
Cross-matching ID
DrugBank ID
DB00026
TTD ID
D02DES
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin 1 receptor type 1 (IL1R1) TTWOTEA IL1R1_HUMAN Antagonist [4]
HUMAN interleukin-1 receptor 1 (IL1R1) TTT7FOP IL1R1_HUMAN Antagonist [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification 15 Disease of the musculoskeletal system/connective tissue
Disease Class ICD-11: FA20 Rheumatoid arthritis
The Studied Tissue Synovial tissue
The Studied Disease Rheumatoid arthritis [ICD-11:FA20]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin 1 receptor type 1 (IL1R1) DTT IL1R1 2.02E-03 0.65 1.01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Anakinra
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Upadacitinib DM32B5U Major Additive immunosuppressive effects by the combination of Anakinra and Upadacitinib. Rheumatoid arthritis [FA20] [6]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Anakinra and Golimumab. Rheumatoid arthritis [FA20] [6]
Dexamethasone DMMWZET Moderate Additive immunosuppressive effects by the combination of Anakinra and Dexamethasone. Rheumatoid arthritis [FA20] [7]
Adalimumab DMQMV1B Major Additive immunosuppressive effects by the combination of Anakinra and Adalimumab. Rheumatoid arthritis [FA20] [6]
Abatacept DMSA8RU Moderate Additive immunosuppressive effects by the combination of Anakinra and Abatacept. Rheumatoid arthritis [FA20] [7]
Coadministration of a Drug Treating the Disease Different from Anakinra (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Thioguanine DM7NKEV Moderate Additive immunosuppressive effects by the combination of Anakinra and Thioguanine. Acute myeloid leukaemia [2A60] [7]
Uracil mustard DMHL7OB Moderate Additive immunosuppressive effects by the combination of Anakinra and Uracil mustard. Acute myeloid leukaemia [2A60] [7]
Midostaurin DMI6E0R Moderate Additive immunosuppressive effects by the combination of Anakinra and Midostaurin. Acute myeloid leukaemia [2A60] [7]
Gemtuzumab ozogamicin DMJ2O7B Moderate Additive immunosuppressive effects by the combination of Anakinra and Gemtuzumab ozogamicin. Acute myeloid leukaemia [2A60] [7]
Idarubicin DMM0XGL Moderate Additive immunosuppressive effects by the combination of Anakinra and Idarubicin. Acute myeloid leukaemia [2A60] [7]
Daunorubicin DMQUSBT Moderate Additive immunosuppressive effects by the combination of Anakinra and Daunorubicin. Acute myeloid leukaemia [2A60] [7]
Oliceridine DM6MDCF Moderate Altered metabolism of Anakinra due to Oliceridine alters the formation of CYP450 enzymes. Acute pain [MG31] [6]
Siltuximab DMGEATB Moderate Additive immunosuppressive effects by the combination of Anakinra and Siltuximab. Anemia [3A00-3A9Z] [7]
Nifedipine DMSVOZT Moderate Altered metabolism of Anakinra due to Nifedipine alters the formation of CYP450 enzymes. Angina pectoris [BA40] [6]
Alprazolam DMC7XDN Moderate Altered metabolism of Anakinra due to Alprazolam alters the formation of CYP450 enzymes. Anxiety disorder [6B00-6B0Z] [6]
Methylphenobarbital DMDSWAG Moderate Altered metabolism of Anakinra due to Methylphenobarbital alters the formation of CYP450 enzymes. Anxiety disorder [6B00-6B0Z] [8]
Clobazam - Lundbeck DMW1OQ0 Moderate Altered metabolism of Anakinra due to Clobazam - Lundbeck alters the formation of CYP450 enzymes. Anxiety disorder [6B00-6B0Z] [6]
Budesonide DMJIBAW Moderate Additive immunosuppressive effects by the combination of Anakinra and Budesonide. Asthma [CA23] [7]
Aminophylline DML2NIB Moderate Altered metabolism of Anakinra due to Aminophylline alters the formation of CYP450 enzymes. Asthma [CA23] [6]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Anakinra and Roflumilast. Asthma [CA23] [6]
Dupilumab DMOAD2Y Moderate Additive immunosuppressive effects by the combination of Anakinra and Dupilumab. Atopic eczema [EA80] [7]
Linezolid DMGFPU2 Moderate Additive immunosuppressive effects by the combination of Anakinra and Linezolid. Bacterial infection [1A00-1C4Z] [7]
Temozolomide DMKECZD Moderate Additive immunosuppressive effects by the combination of Anakinra and Temozolomide. Brain cancer [2A00] [7]
Lomustine DMMWSUL Moderate Additive immunosuppressive effects by the combination of Anakinra and Lomustine. Brain cancer [2A00] [7]
Eribulin DM1DX4Q Moderate Additive immunosuppressive effects by the combination of Anakinra and Eribulin. Breast cancer [2C60-2C6Y] [7]
Talazoparib DM1KS78 Moderate Additive immunosuppressive effects by the combination of Anakinra and Talazoparib. Breast cancer [2C60-2C6Y] [7]
Ixabepilone DM2OZ3G Moderate Additive immunosuppressive effects by the combination of Anakinra and Ixabepilone. Breast cancer [2C60-2C6Y] [7]
LY2835219 DM93VBZ Moderate Additive immunosuppressive effects by the combination of Anakinra and LY2835219. Breast cancer [2C60-2C6Y] [7]
Pralatrexate DMAO80I Moderate Additive immunosuppressive effects by the combination of Anakinra and Pralatrexate. Breast cancer [2C60-2C6Y] [7]
Palbociclib DMD7L94 Moderate Additive immunosuppressive effects by the combination of Anakinra and Palbociclib. Breast cancer [2C60-2C6Y] [7]
Mitomycin DMH0ZJE Moderate Additive immunosuppressive effects by the combination of Anakinra and Mitomycin. Breast cancer [2C60-2C6Y] [7]
Thiotepa DMIZKOP Moderate Additive immunosuppressive effects by the combination of Anakinra and Thiotepa. Breast cancer [2C60-2C6Y] [7]
Cabazitaxel DMPAZHC Moderate Additive immunosuppressive effects by the combination of Anakinra and Cabazitaxel. Breast cancer [2C60-2C6Y] [7]
Bosutinib DMTI8YE Moderate Additive immunosuppressive effects by the combination of Anakinra and Bosutinib. Breast cancer [2C60-2C6Y] [7]
Trastuzumab DMZQOUX Moderate Additive immunosuppressive effects by the combination of Anakinra and Trastuzumab. Breast cancer [2C60-2C6Y] [7]
Atorvastatin DMF28YC Moderate Altered metabolism of Anakinra due to Atorvastatin alters the formation of CYP450 enzymes. Cardiovascular disease [BA00-BE2Z] [6]
Corticotropin DMP9TWZ Moderate Additive immunosuppressive effects by the combination of Anakinra and Corticotropin. Chronic kidney disease [GB61] [7]
Irinotecan DMP6SC2 Moderate Additive immunosuppressive effects by the combination of Anakinra and Irinotecan. Colorectal cancer [2B91] [7]
Oxaliplatin DMQNWRD Moderate Additive immunosuppressive effects by the combination of Anakinra and Oxaliplatin. Colorectal cancer [2B91] [7]
Aflibercept DMT3D5I Moderate Additive immunosuppressive effects by the combination of Anakinra and Aflibercept. Colorectal cancer [2B91] [7]
Capecitabine DMTS85L Moderate Additive immunosuppressive effects by the combination of Anakinra and Capecitabine. Colorectal cancer [2B91] [7]
Drospirenone DM1A9W3 Moderate Altered metabolism of Anakinra due to Drospirenone alters the formation of CYP450 enzymes. Contraceptive management [QA21] [6]
Levonorgestrel DM1DP7T Moderate Altered metabolism of Anakinra due to Levonorgestrel alters the formation of CYP450 enzymes. Contraceptive management [QA21] [6]
Mestranol DMG3F94 Moderate Altered metabolism of Anakinra due to Mestranol alters the formation of CYP450 enzymes. Contraceptive management [QA21] [8]
Etonogestrel DMKA8J4 Moderate Altered metabolism of Anakinra due to Etonogestrel alters the formation of CYP450 enzymes. Contraceptive management [QA21] [6]
Norgestimate DMYP4XC Moderate Altered metabolism of Anakinra due to Norgestimate alters the formation of CYP450 enzymes. Contraceptive management [QA21] [8]
Lidocaine DML4ZOT Moderate Altered metabolism of Anakinra due to Lidocaine alters the formation of CYP450 enzymes. Corneal disease [9A76-9A78] [6]
Nimodipine DMQ0RKZ Moderate Altered metabolism of Anakinra due to Nimodipine alters the formation of CYP450 enzymes. Coronary vasospastic disease [BA85] [6]
Oxtriphylline DMLHSE3 Moderate Altered metabolism of Anakinra due to Oxtriphylline alters the formation of CYP450 enzymes. Cough [MD12] [6]
Methadone DMTW6IU Moderate Altered metabolism of Anakinra due to Methadone alters the formation of CYP450 enzymes. Cough [MD12] [6]
Mycophenolic acid DMRBMAU Moderate Additive immunosuppressive effects by the combination of Anakinra and Mycophenolic acid. Crohn disease [DD70] [7]
Rivaroxaban DMQMBZ1 Moderate Altered metabolism of Anakinra due to Rivaroxaban alters the formation of CYP450 enzymes. Deep vein thrombosis [BD71] [6]
Polatuzumab vedotin DMF6Y0L Moderate Additive immunosuppressive effects by the combination of Anakinra and Polatuzumab vedotin. Diffuse large B-cell lymphoma [2A81] [7]
Axicabtagene ciloleucel DMYHN59 Moderate Additive immunosuppressive effects by the combination of Anakinra and Axicabtagene ciloleucel. Diffuse large B-cell lymphoma [2A81] [7]
PMID28870136-Compound-48 DMPIM9L Moderate Altered metabolism of Anakinra due to PMID28870136-Compound-48 alters the formation of CYP450 enzymes. Discovery agent [N.A.] [6]
Oestradiol valerate and dienogest DMZK0FQ Moderate Altered metabolism of Anakinra due to Oestradiol valerate and dienogest alters the formation of CYP450 enzymes. Endometriosis [GA10] [8]
Diazepam DM08E9O Moderate Altered metabolism of Anakinra due to Diazepam alters the formation of CYP450 enzymes. Epilepsy/seizure [8A61-8A6Z] [6]
Primidone DM0WX6I Moderate Altered metabolism of Anakinra due to Primidone alters the formation of CYP450 enzymes. Epilepsy/seizure [8A61-8A6Z] [6]
Mephenytoin DM5UGDK Moderate Altered metabolism of Anakinra due to Mephenytoin alters the formation of CYP450 enzymes. Epilepsy/seizure [8A61-8A6Z] [6]
Ethosuximide DMDZ9LT Moderate Altered metabolism of Anakinra due to Ethosuximide alters the formation of CYP450 enzymes. Epilepsy/seizure [8A61-8A6Z] [6]
Phenytoin DMNOKBV Moderate Altered metabolism of Anakinra due to Phenytoin alters the formation of CYP450 enzymes. Epilepsy/seizure [8A61-8A6Z] [6]
Fosphenytoin DMOX3LB Moderate Altered metabolism of Anakinra due to Fosphenytoin alters the formation of CYP450 enzymes. Epilepsy/seizure [8A61-8A6Z] [6]
Clonazepam DMTO13J Moderate Altered metabolism of Anakinra due to Clonazepam alters the formation of CYP450 enzymes. Epilepsy/seizure [8A61-8A6Z] [6]
Phenobarbital DMXZOCG Moderate Altered metabolism of Anakinra due to Phenobarbital alters the formation of CYP450 enzymes. Epilepsy/seizure [8A61-8A6Z] [6]
Carbamazepine DMZOLBI Moderate Altered metabolism of Anakinra due to Carbamazepine alters the formation of CYP450 enzymes. Epilepsy/seizure [8A61-8A6Z] [6]
Nicardipine DMCDYW7 Moderate Altered metabolism of Anakinra due to Nicardipine alters the formation of CYP450 enzymes. Essential hypertension [BA00] [6]
Bay 80-6946 DMLOS5R Moderate Additive immunosuppressive effects by the combination of Anakinra and Bay 80-6946. Follicular lymphoma [2A80] [7]
Avapritinib DMK2GZX Moderate Additive immunosuppressive effects by the combination of Anakinra and Avapritinib. Gastrointestinal stromal tumour [2B5B] [7]
177Lu-DOTATATE DMT8GVU Moderate Additive immunosuppressive effects by the combination of Anakinra and 177Lu-DOTATATE. Hepatitis virus infection [1E50-1E51] [7]
Procarbazine DMIK367 Moderate Additive immunosuppressive effects by the combination of Anakinra and Procarbazine. Hodgkin lymphoma [2B30] [7]
Bleomycin DMNER5S Moderate Additive immunosuppressive effects by the combination of Anakinra and Bleomycin. Hodgkin lymphoma [2B30] [7]
Brentuximab vedotin DMWLC57 Moderate Additive immunosuppressive effects by the combination of Anakinra and Brentuximab vedotin. Hodgkin lymphoma [2B30] [7]
Zidovudine DM4KI7O Moderate Additive immunosuppressive effects by the combination of Anakinra and Zidovudine. Human immunodeficiency virus disease [1C60-1C62] [7]
Simvastatin DM30SGU Moderate Altered metabolism of Anakinra due to Simvastatin alters the formation of CYP450 enzymes. Hyper-lipoproteinaemia [5C80] [6]
Lovastatin DM9OZWQ Moderate Altered metabolism of Anakinra due to Lovastatin alters the formation of CYP450 enzymes. Hyper-lipoproteinaemia [5C80] [6]
Nisoldipine DM7ISKJ Moderate Altered metabolism of Anakinra due to Nisoldipine alters the formation of CYP450 enzymes. Hypertension [BA00-BA04] [6]
Levamlodipine DM92S6N Moderate Altered metabolism of Anakinra due to Levamlodipine alters the formation of CYP450 enzymes. Hypertension [BA00-BA04] [6]
Isradipine DMA5XGH Moderate Altered metabolism of Anakinra due to Isradipine alters the formation of CYP450 enzymes. Hypertension [BA00-BA04] [6]
Amlodipine DMBDAZV Moderate Altered metabolism of Anakinra due to Amlodipine alters the formation of CYP450 enzymes. Hypertension [BA00-BA04] [6]
Felodipine DMOSW35 Moderate Altered metabolism of Anakinra due to Felodipine alters the formation of CYP450 enzymes. Hypertension [BA00-BA04] [6]
Fludrocortisone DMUDIR8 Moderate Additive immunosuppressive effects by the combination of Anakinra and Fludrocortisone. Hypo-osmolality/hyponatraemia [5C72] [7]
Triazolam DMETYK5 Moderate Altered metabolism of Anakinra due to Triazolam alters the formation of CYP450 enzymes. Insomnia [7A00-7A0Z] [6]
Olaratumab DMNYOIX Moderate Additive immunosuppressive effects by the combination of Anakinra and Olaratumab. Kaposi sarcoma [2B57] [7]
Methotrexate DM2TEOL Moderate Additive immunosuppressive effects by the combination of Anakinra and Methotrexate. Leukaemia [2A60-2B33] [7]
Nelarabine DMB6VEG Moderate Additive immunosuppressive effects by the combination of Anakinra and Nelarabine. Leukaemia [2A60-2B33] [7]
DTI-015 DMXZRW0 Moderate Additive immunosuppressive effects by the combination of Anakinra and DTI-015. Liver cancer [2C12] [7]
Denosumab DMNI0KO Moderate Additive immunosuppressive effects by the combination of Anakinra and Denosumab. Low bone mass disorder [FB83] [9]
Brigatinib DM7W94S Moderate Additive immunosuppressive effects by the combination of Anakinra and Brigatinib. Lung cancer [2C25] [7]
Lurbinectedin DMEFRTZ Moderate Additive myelosuppressive effects by the combination of Anakinra and Lurbinectedin. Lung cancer [2C25] [6]
Osimertinib DMRJLAT Moderate Additive immunosuppressive effects by the combination of Anakinra and Osimertinib. Lung cancer [2C25] [7]
Belimumab DM3OBQF Moderate Additive immunosuppressive effects by the combination of Anakinra and Belimumab. Lupus erythematosus [4A40] [7]
Inotuzumab ozogamicin DMAC130 Moderate Additive immunosuppressive effects by the combination of Anakinra and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [7]
Rituximab DM1YVZT Moderate Additive immunosuppressive effects by the combination of Anakinra and Rituximab. Malignant haematopoietic neoplasm [2B33] [7]
Tositumomab DMMYZ3D Moderate Additive immunosuppressive effects by the combination of Anakinra and Tositumomab. Malignant haematopoietic neoplasm [2B33] [7]
Fludarabine DMVRLT7 Moderate Additive immunosuppressive effects by the combination of Anakinra and Fludarabine. Malignant haematopoietic neoplasm [2B33] [7]
Pentostatin DM0HXDS Moderate Additive immunosuppressive effects by the combination of Anakinra and Pentostatin. Mature B-cell leukaemia [2A82] [7]
Ofatumumab DM295PR Moderate Additive immunosuppressive effects by the combination of Anakinra and Ofatumumab. Mature B-cell leukaemia [2A82] [7]
Obinutuzumab DM3BVAE Moderate Additive immunosuppressive effects by the combination of Anakinra and Obinutuzumab. Mature B-cell leukaemia [2A82] [7]
Cladribine DM3JDRP Major Additive immunosuppressive effects by the combination of Anakinra and Cladribine. Mature B-cell leukaemia [2A82] [6]
Idelalisib DM602WT Moderate Additive immunosuppressive effects by the combination of Anakinra and Idelalisib. Mature B-cell leukaemia [2A82] [7]
GDC-0199 DMH0QKA Moderate Additive immunosuppressive effects by the combination of Anakinra and GDC-0199. Mature B-cell leukaemia [2A82] [7]
Chlorambucil DMRKE63 Moderate Additive immunosuppressive effects by the combination of Anakinra and Chlorambucil. Mature B-cell leukaemia [2A82] [7]
IPI-145 DMWA24P Moderate Additive immunosuppressive effects by the combination of Anakinra and IPI-145. Mature B-cell leukaemia [2A82] [7]
Alemtuzumab DMZL3IV Moderate Additive immunosuppressive effects by the combination of Anakinra and Alemtuzumab. Mature B-cell leukaemia [2A82] [10]
Acalabrutinib DM7GCVW Moderate Additive immunosuppressive effects by the combination of Anakinra and Acalabrutinib. Mature B-cell lymphoma [2A85] [7]
Clofarabine DMCVJ86 Moderate Additive immunosuppressive effects by the combination of Anakinra and Clofarabine. Mature B-cell lymphoma [2A85] [7]
Blinatumomab DMGECIJ Moderate Additive immunosuppressive effects by the combination of Anakinra and Blinatumomab. Mature B-cell lymphoma [2A85] [7]
Ibrutinib DMHZCPO Moderate Additive immunosuppressive effects by the combination of Anakinra and Ibrutinib. Mature B-cell lymphoma [2A85] [7]
Vincristine DMINOX3 Moderate Additive immunosuppressive effects by the combination of Anakinra and Vincristine. Mature B-cell lymphoma [2A85] [6]
Teniposide DMLW57T Moderate Additive immunosuppressive effects by the combination of Anakinra and Teniposide. Mature B-cell lymphoma [2A85] [7]
Tisagenlecleucel DMM9BJD Moderate Additive immunosuppressive effects by the combination of Anakinra and Tisagenlecleucel. Mature B-cell lymphoma [2A85] [7]
Mercaptopurine DMTM2IK Moderate Additive immunosuppressive effects by the combination of Anakinra and Mercaptopurine. Mature B-cell lymphoma [2A85] [7]
Ponatinib DMYGJQO Moderate Additive immunosuppressive effects by the combination of Anakinra and Ponatinib. Mature B-cell lymphoma [2A85] [7]
Cytarabine DMZD5QR Moderate Additive immunosuppressive effects by the combination of Anakinra and Cytarabine. Mature B-cell lymphoma [2A85] [7]
Mechlorethamine DM0CVXA Moderate Additive immunosuppressive effects by the combination of Anakinra and Mechlorethamine. Mature T-cell lymphoma [2A90] [7]
Dacarbazine DMNPZL4 Moderate Additive immunosuppressive effects by the combination of Anakinra and Dacarbazine. Melanoma [2C30] [7]
Ethinyl estradiol DMODJ40 Moderate Altered metabolism of Anakinra due to Ethinyl estradiol alters the formation of CYP450 enzymes. Menopausal disorder [GA30] [8]
Midazolam DMXOELT Moderate Altered metabolism of Anakinra due to Midazolam alters the formation of CYP450 enzymes. Mood/affect symptom [MB24] [6]
Carfilzomib DM48K0X Moderate Additive immunosuppressive effects by the combination of Anakinra and Carfilzomib. Multiple myeloma [2A83] [7]
Panobinostat DM58WKG Moderate Additive immunosuppressive effects by the combination of Anakinra and Panobinostat. Multiple myeloma [2A83] [7]
Lenalidomide DM6Q7U4 Moderate Additive immunosuppressive effects by the combination of Anakinra and Lenalidomide. Multiple myeloma [2A83] [7]
Thalidomide DM70BU5 Moderate Additive immunosuppressive effects by the combination of Anakinra and Thalidomide. Multiple myeloma [2A83] [7]
Selinexor DMBD4K3 Moderate Additive immunosuppressive effects by the combination of Anakinra and Selinexor. Multiple myeloma [2A83] [7]
Belantamab mafodotin DMBT3AI Moderate Additive immunosuppressive effects by the combination of Anakinra and Belantamab mafodotin. Multiple myeloma [2A83] [7]
Elotuzumab DMEYHG9 Moderate Additive immunosuppressive effects by the combination of Anakinra and Elotuzumab. Multiple myeloma [2A83] [7]
Daratumumab DMKCIUZ Moderate Additive immunosuppressive effects by the combination of Anakinra and Daratumumab. Multiple myeloma [2A83] [7]
Bortezomib DMNO38U Moderate Additive immunosuppressive effects by the combination of Anakinra and Bortezomib. Multiple myeloma [2A83] [7]
Melphalan DMOLNHF Moderate Additive immunosuppressive effects by the combination of Anakinra and Melphalan. Multiple myeloma [2A83] [7]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Anakinra and Tecfidera. Multiple sclerosis [8A40] [7]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Anakinra and Siponimod. Multiple sclerosis [8A40] [11]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Anakinra and Fingolimod. Multiple sclerosis [8A40] [12]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Anakinra and Ocrelizumab. Multiple sclerosis [8A40] [7]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Anakinra and Ozanimod. Multiple sclerosis [8A40] [6]
Deflazacort DMV0RNS Moderate Additive immunosuppressive effects by the combination of Anakinra and Deflazacort. Muscular dystrophy [8C70] [7]
Bexarotene DMOBIKY Moderate Additive immunosuppressive effects by the combination of Anakinra and Bexarotene. Mycosis fungoides [2B01] [7]
Romidepsin DMT5GNL Moderate Additive immunosuppressive effects by the combination of Anakinra and Romidepsin. Mycosis fungoides [2B01] [7]
Decitabine DMQL8XJ Moderate Additive immunosuppressive effects by the combination of Anakinra and Decitabine. Myelodysplastic syndrome [2A37] [7]
Azacitidine DMTA5OE Moderate Additive immunosuppressive effects by the combination of Anakinra and Azacitidine. Myelodysplastic syndrome [2A37] [7]
Nilotinib DM7HXWT Moderate Additive immunosuppressive effects by the combination of Anakinra and Nilotinib. Myeloproliferative neoplasm [2A20] [7]
Ruxolitinib DM7Q98D Moderate Additive immunosuppressive effects by the combination of Anakinra and Ruxolitinib. Myeloproliferative neoplasm [2A20] [7]
Imatinib DM7RJXL Moderate Additive immunosuppressive effects by the combination of Anakinra and Imatinib. Myeloproliferative neoplasm [2A20] [7]
Dasatinib DMJV2EK Moderate Additive immunosuppressive effects by the combination of Anakinra and Dasatinib. Myeloproliferative neoplasm [2A20] [7]
Hydroxyurea DMOQVU9 Moderate Additive immunosuppressive effects by the combination of Anakinra and Hydroxyurea. Myeloproliferative neoplasm [2A20] [7]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive immunosuppressive effects by the combination of Anakinra and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [7]
Busulfan DMXYJ9C Moderate Additive immunosuppressive effects by the combination of Anakinra and Busulfan. Myeloproliferative neoplasm [2A20] [7]
Inebilizumab DMI0RHA Moderate Additive immunosuppressive effects by the combination of Anakinra and Inebilizumab. Nervous system paraneoplastic/autoimmune disorder [8E4A] [7]
Atezolizumab DMMF8U0 Moderate Additive immunosuppressive effects by the combination of Anakinra and Atezolizumab. Non-small cell lung cancer [2C25] [7]
Olaparib DM8QB1D Moderate Additive immunosuppressive effects by the combination of Anakinra and Olaparib. Ovarian cancer [2C73] [7]
Carboplatin DMG281S Moderate Additive immunosuppressive effects by the combination of Anakinra and Carboplatin. Ovarian cancer [2C73] [7]
Altretamine DMKLAYG Moderate Additive immunosuppressive effects by the combination of Anakinra and Altretamine. Ovarian cancer [2C73] [7]
MK-4827 DMLYGH4 Moderate Additive immunosuppressive effects by the combination of Anakinra and MK-4827. Ovarian cancer [2C73] [7]
Topotecan DMP6G8T Moderate Additive immunosuppressive effects by the combination of Anakinra and Topotecan. Ovarian cancer [2C73] [7]
Buprenorphine DMPRI8G Moderate Altered metabolism of Anakinra due to Buprenorphine alters the formation of CYP450 enzymes. Pain [MG30-MG3Z] [6]
Hydrocodone DMQ2JO5 Moderate Altered metabolism of Anakinra due to Hydrocodone alters the formation of CYP450 enzymes. Pain [MG30-MG3Z] [6]
Streptozocin DMOF7AT Moderate Additive immunosuppressive effects by the combination of Anakinra and Streptozocin. Pancreatic cancer [2C10] [7]
Levamisole DM5EN79 Moderate Additive immunosuppressive effects by the combination of Anakinra and Levamisole. Parasitic infection [1D0Y-1G2Z] [7]
Pemetrexed DMMX2E6 Moderate Additive immunosuppressive effects by the combination of Anakinra and Pemetrexed. Pleural mesothelioma [2C26] [7]
Prednisone DM2HG4X Moderate Additive immunosuppressive effects by the combination of Anakinra and Prednisone. Postoperative inflammation [1A00-CA43] [7]
Betamethasone DMAHJEF Moderate Additive immunosuppressive effects by the combination of Anakinra and Betamethasone. Postoperative inflammation [1A00-CA43] [7]
Hydrocortisone DMGEMB7 Moderate Additive immunosuppressive effects by the combination of Anakinra and Hydrocortisone. Postoperative inflammation [1A00-CA43] [7]
Brodalumab DMASDQ6 Moderate Additive immunosuppressive effects by the combination of Anakinra and Brodalumab. Psoriasis [EA90] [7]
Efalizumab DMCKL5V Moderate Additive immunosuppressive effects by the combination of Anakinra and Efalizumab. Psoriasis [EA90] [13]
Infliximab DMH7OIA Major Additive immunosuppressive effects by the combination of Anakinra and Infliximab. Psoriasis [EA90] [6]
Ustekinumab DMHTYK3 Moderate Additive immunosuppressive effects by the combination of Anakinra and Ustekinumab. Psoriasis [EA90] [7]
Tildrakizumab DMLW9HG Moderate Additive immunosuppressive effects by the combination of Anakinra and Tildrakizumab. Psoriasis [EA90] [7]
Risankizumab DMM32GT Moderate Additive immunosuppressive effects by the combination of Anakinra and Risankizumab. Psoriasis [EA90] [7]
Ixekizumab DMXW92T Moderate Additive immunosuppressive effects by the combination of Anakinra and Ixekizumab. Psoriasis [EA90] [7]
Aldesleukin DM4YMIS Moderate Additive immunosuppressive effects by the combination of Anakinra and Aldesleukin. Renal cell carcinoma [2C90] [7]
Everolimus DM8X2EH Moderate Additive immunosuppressive effects by the combination of Anakinra and Everolimus. Renal cell carcinoma [2C90] [6]
Temsirolimus DMS104F Moderate Additive myelosuppressive effects by the combination of Anakinra and Temsirolimus. Renal cell carcinoma [2C90] [6]
Fentanyl DM8WAHT Moderate Altered metabolism of Anakinra due to Fentanyl alters the formation of CYP450 enzymes. Sensation disturbance [MB40] [6]
Sufentanil DMU7YEL Moderate Altered metabolism of Anakinra due to Sufentanil alters the formation of CYP450 enzymes. Sensation disturbance [MB40] [6]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Anakinra when combined with Anthrax vaccine. Sepsis [1G40-1G41] [14]
Mogamulizumab DMISH0Z Moderate Additive immunosuppressive effects by the combination of Anakinra and Mogamulizumab. Sezary syndrome [2B02] [7]
Floxuridine DM04LR2 Moderate Additive immunosuppressive effects by the combination of Anakinra and Floxuridine. Solid tumour/cancer [2A00-2F9Z] [7]
Dactinomycin DM2YGNW Moderate Additive immunosuppressive effects by the combination of Anakinra and Dactinomycin. Solid tumour/cancer [2A00-2F9Z] [7]
Cyclophosphamide DM4O2Z7 Moderate Additive immunosuppressive effects by the combination of Anakinra and Cyclophosphamide. Solid tumour/cancer [2A00-2F9Z] [7]
Vinblastine DM5TVS3 Moderate Additive immunosuppressive effects by the combination of Anakinra and Vinblastine. Solid tumour/cancer [2A00-2F9Z] [6]
PDX-101 DM6OC53 Moderate Additive immunosuppressive effects by the combination of Anakinra and PDX-101. Solid tumour/cancer [2A00-2F9Z] [7]
Ifosfamide DMCT3I8 Moderate Additive immunosuppressive effects by the combination of Anakinra and Ifosfamide. Solid tumour/cancer [2A00-2F9Z] [7]
Docetaxel DMDI269 Moderate Additive immunosuppressive effects by the combination of Anakinra and Docetaxel. Solid tumour/cancer [2A00-2F9Z] [7]
Trabectedin DMG3Y89 Moderate Additive immunosuppressive effects by the combination of Anakinra and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [7]
Mitoxantrone DMM39BF Moderate Additive immunosuppressive effects by the combination of Anakinra and Mitoxantrone. Solid tumour/cancer [2A00-2F9Z] [7]
Etoposide DMNH3PG Moderate Additive immunosuppressive effects by the combination of Anakinra and Etoposide. Solid tumour/cancer [2A00-2F9Z] [7]
Epirubicin DMPDW6T Moderate Additive immunosuppressive effects by the combination of Anakinra and Epirubicin. Solid tumour/cancer [2A00-2F9Z] [7]
Prednisolone DMQ8FR2 Moderate Additive immunosuppressive effects by the combination of Anakinra and Prednisolone. Solid tumour/cancer [2A00-2F9Z] [7]
Cisplatin DMRHGI9 Moderate Additive immunosuppressive effects by the combination of Anakinra and Cisplatin. Solid tumour/cancer [2A00-2F9Z] [7]
Gemcitabine DMSE3I7 Moderate Additive immunosuppressive effects by the combination of Anakinra and Gemcitabine. Solid tumour/cancer [2A00-2F9Z] [7]
Norethindrone DMTY169 Moderate Altered metabolism of Anakinra due to Norethindrone alters the formation of CYP450 enzymes. Solid tumour/cancer [2A00-2F9Z] [8]
Fluorouracil DMUM7HZ Moderate Additive immunosuppressive effects by the combination of Anakinra and Fluorouracil. Solid tumour/cancer [2A00-2F9Z] [7]
Taxol DMUOT9V Moderate Additive immunosuppressive effects by the combination of Anakinra and Taxol. Solid tumour/cancer [2A00-2F9Z] [7]
Doxorubicin DMVP5YE Moderate Additive immunosuppressive effects by the combination of Anakinra and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [7]
Vinorelbine DMVXFYE Moderate Additive myelosuppressive effects by the combination of Anakinra and Vinorelbine. Solid tumour/cancer [2A00-2F9Z] [6]
Warfarin DMJYCVW Moderate Altered metabolism of Anakinra due to Warfarin alters the formation of CYP450 enzymes. Supraventricular tachyarrhythmia [BC81] [6]
Pomalidomide DMTGBAX Moderate Additive immunosuppressive effects by the combination of Anakinra and Pomalidomide. Systemic sclerosis [4A42] [7]
Plicamycin DM7C8YV Moderate Additive immunosuppressive effects by the combination of Anakinra and Plicamycin. Testicular cancer [2C80] [7]
Apixaban DM89JLN Moderate Altered metabolism of Anakinra due to Apixaban alters the formation of CYP450 enzymes. Thrombosis [DB61-GB90] [6]
Dicumarol DMFQCB1 Moderate Altered metabolism of Anakinra due to Dicumarol alters the formation of CYP450 enzymes. Thrombosis [DB61-GB90] [8]
Trimetrexate DMDEA85 Moderate Additive immunosuppressive effects by the combination of Anakinra and Trimetrexate. Toxoplasmosis [1F57] [7]
Muromonab DM8ANCF Moderate Additive immunosuppressive effects by the combination of Anakinra and Muromonab. Transplant rejection [NE84] [7]
Sirolimus DMGW1ID Moderate Additive myelosuppressive effects by the combination of Anakinra and Sirolimus. Transplant rejection [NE84] [6]
Azathioprine DMMZSXQ Moderate Additive immunosuppressive effects by the combination of Anakinra and Azathioprine. Transplant rejection [NE84] [7]
Mycophenolate mofetil DMPQAGE Moderate Additive immunosuppressive effects by the combination of Anakinra and Mycophenolate mofetil. Transplant rejection [NE84] [7]
Basiliximab DMWNRZT Moderate Additive immunosuppressive effects by the combination of Anakinra and Basiliximab. Transplant rejection [NE84] [7]
Belatacept DMXLYQF Moderate Additive immunosuppressive effects by the combination of Anakinra and Belatacept. Transplant rejection [NE84] [7]
Tacrolimus DMZ7XNQ Moderate Additive myelosuppressive effects by the combination of Anakinra and Tacrolimus. Transplant rejection [NE84] [6]
Durvalumab DM4PVDY Moderate Additive immunosuppressive effects by the combination of Anakinra and Durvalumab. Ureteral cancer [2C92] [7]
Triamcinolone DM98IXF Moderate Additive immunosuppressive effects by the combination of Anakinra and Triamcinolone. Vasomotor/allergic rhinitis [CA08] [7]
Disopyramide DM5SYZP Moderate Altered metabolism of Anakinra due to Disopyramide alters the formation of CYP450 enzymes. Ventricular tachyarrhythmia [BC71] [6]
Mexiletine DMCTE9R Moderate Altered metabolism of Anakinra due to Mexiletine alters the formation of CYP450 enzymes. Ventricular tachyarrhythmia [BC71] [6]
Procainamide DMNMXR8 Moderate Altered metabolism of Anakinra due to Procainamide alters the formation of CYP450 enzymes. Ventricular tachyarrhythmia [BC71] [6]
Propafenone DMPIBJK Moderate Altered metabolism of Anakinra due to Propafenone alters the formation of CYP450 enzymes. Ventricular tachyarrhythmia [BC71] [6]
Flecainide DMSQDLE Moderate Altered metabolism of Anakinra due to Flecainide alters the formation of CYP450 enzymes. Ventricular tachyarrhythmia [BC71] [6]
Trifluridine DMG2YBD Moderate Additive immunosuppressive effects by the combination of Anakinra and Trifluridine. Virus infection [1A24-1D9Z] [7]
⏷ Show the Full List of 209 DDI Information of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (BLA) 103950.
2 ClinicalTrials.gov (NCT04364009) Anakinra for COVID-19 Respiratory Symptoms. U.S. National Institutes of Health.
3 Clinical and genetic characterization of Italian patients affected by CINCA syndrome. Rheumatology (Oxford). 2007 Mar;46(3):473-8.
4 IL-1 receptor antagonism and muscle gene expression in patients with type 2 diabetes. Eur Cytokine Netw. 2009 Jun 1;20(2):81-87.
5 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (BLA) 125166.
6 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
7 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
8 Product Information. Cosentyx (secukinumab). Novartis Pharmaceuticals, East Hanover, NJ.
9 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
10 Product Information. Campath (alemtuzumab) Berlex, Richmond, CA.
11 Cerner Multum, Inc. "Australian Product Information.".
12 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
13 Product Information. Raptiva (efalizumab). Genentech, South San Francisco, CA.
14 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]